Sign In
Last checked at 
9 May 2014 16:19
ο»Ώ
Β
Avacta Group plc
("Avacta" or the "Group")
Β
Director's dealing
Β
Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for human and animal healthcare, announces that Craig Slater, Chief Operating Officer of the Group, has today purchased 641,025 Ordinary Shares of 0.1p each in the Group at a price of 1.17 pence per share.
Β
Following this transaction, Mr Slater's total interest in the Group is 34,723,111 Ordinary Shares of 0.1p each, representing approximately 0.9% of Avacta's issued share capital.
Β
Enquiries:
Β
Avacta Group plc | Tel: +44 (0) 844 414 0452 | |
Alastair Smith, Chief Executive Officer | www.avacta.com | |
Tim Sykes, Chief Financial Officer | ||
Numis Securities Limited | Tel: +44 (0) 207 260 1000 | |
Michael Meade / Freddie Barnfield - Nominated Adviser | www.numiscorp.com | |
James Black - Corporate Broking | ||
Walbrook PR Ltd | Tel: +44 (0) 20 7933 8780 or avacta@walbrookpr.com | |
Anna Dunphy | Mob: +44 (0)7876 741 001 | |
Lianne Cawthorne | Mob: +44 (0)7584 391 303 | |
Β
Β
About Avacta Group plc - www.avacta.com
Β
Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through three divisions:
Β
Avacta Analytical www.avactaanalytical.com Β | High throughput analysis instrument, Optim, to help reduce the cost and risk of drug development. |
Avacta Animal Health www.avactaanimalhealth.com Β | Veterinary diagnostics reference laboratory, diagnostic kits and newly launched in-clinic blood analyser, Sensipod. |
Avacta Life Sciences www.avactalifesciences.com Β | Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development. |
Β
Avacta joined AIM in August 2006 and is based in Wetherby, England.
Β
Follow the stocks
